Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical reports topline results from phase 3 paediatric IsoCOMFORT study
Regulatory
Sedana Medical AB (publ) today announces that the primary endpoint of its Phase 3 IsoCOMFORT study w…
Report from Sedana Medical AB’s annual general meeting on May 16, 2023
Regulatory
Sedana Medical AB’s annual general meeting was held on Tuesday, May 16, 2023. The main resolutions p…
Sedana Medical AB’s Interim report January-March 2023
Regulatory
Back to growth
Financial Calendar
| Year-End Report 2022 | 16 February 2023 | 07:00 |
| Annual Report 2022 | 03 April 2023 | 00:00 |
